SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.

[thanhclub69]

Prostate. 2010 Feb 1;70(2):170-8.
SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
Wang C, Tao W, Chen Q, Hu H, Wen XY, Han R.
SourceTianjin Institute of Urological Surgery, Tianjin Key Laboratory of Urology, Tianjin Medical University, Tianjin, China.
AbstractBACKGROUND: Increasing studies investigating the association between steroid 5-alpha reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to prostate cancer (PCa) confer inconsistent results. To precisely estimate the relationship with more statistical power, a meta-analysis was performed.METHODS: A comprehensive search was conducted to identify all case-control studies investigating such an association. Odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the size effect.RESULTS: Twenty-five eligible reports were identified including 8,615 cases/9,089 controls in 33 comparisons. In overall analysis, no significant associations were found in all genetic models. Subgroup analyses by ethnicity revealed that small excess PCa risks were observed in dominant model (OR, 1.11; 95% CI, 1.03-1.19 for (LL VL) vs. VV; P andlt; 0.01; P(heterogeneity) = 0.49) and L allele frequency comparison (OR, 1.09; 1.03-1.15 for L allele frequency; P andlt; 0.01; P(heterogeneity) = 0.07) in Europeans. Meanwhile, SRD5A2 V89L polymorphism was significantly associated with an increased PCa risk in men aged andlt; or =65 under the co-dominant (OR, 1.70; 95% CI, 1.09-2.66 for LL vs. VV; P = 0.02; P(heterogeneity) = 0.31) and recessive (OR, 1.75; 95% CI, 1.14-2.68 for LL vs. (VV VL); P = 0.01; P(heterogeneity) = 0.12) models. However, no significant associations were found in Asians and Africans.CONCLUSIONS: Our study suggests SRD5A2 V89L polymorphism could play a low-penetrant role in PCa risk among Europeans and individuals younger than 65 years. Additional well-designed studies are warranted to validate these findings.
PMID: 19760631 [PubMed - indexed for MEDLINE]

[Shahid]

This meta analysis of all studies investigating association between steroid 5-alpha reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to prostate cancer (PCa) produces valuable results by suggesting that SRD5A2 V89L polymorphism could play a low-penetrant role in PCa risk among Europeans and individuals younger than 65 years and also warrants additional well-designed studies to validate findings.